Trials / Completed
CompletedNCT02908282
Topical Omega-3 Fatty Acids (REMOGEN® OMEGA) in the Treatment of Dry Eye
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- TRB Chemedica AG · Industry
- Sex
- All
- Age
- 18 Years – 81 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the efficacy of REMOGEN® OMEGA in reducing Dry Eye Syndrome (DES) symptoms.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | REMOGEN OMEGA | Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml. |
| DEVICE | Povidone | Artificial tears: preservative-free eye drops containing 2% povidone. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2018-07-01
- Completion
- 2018-07-01
- First posted
- 2016-09-20
- Last updated
- 2018-08-15
Locations
5 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02908282. Inclusion in this directory is not an endorsement.